Arete Wealth Advisors LLC Takes $312,000 Position in Natera, Inc. (NASDAQ:NTRA)

Arete Wealth Advisors LLC bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1,982 shares of the medical research company's stock, valued at approximately $312,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its position in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc lifted its holdings in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after buying an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after buying an additional 261 shares during the last quarter. Principal Securities Inc. grew its stake in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in shares of Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after acquiring an additional 332 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Natera Stock Performance

NTRA traded up $4.76 during trading on Friday, reaching $148.04. 1,364,917 shares of the company were exchanged, compared to its average volume of 1,394,665. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The stock has a market cap of $20.01 billion, a P/E ratio of -84.11 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $152.66 and a 200 day moving average of $152.05.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Robert W. Baird increased their price target on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Royal Bank of Canada assumed coverage on Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price for the company. StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. BTIG Research reiterated a "buy" rating on shares of Natera in a research note on Friday, February 28th. Finally, Piper Sandler boosted their target price on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Natera currently has an average rating of "Moderate Buy" and an average price target of $175.76.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 946 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08. Following the completion of the transaction, the chief financial officer now directly owns 109,474 shares of the company's stock, valued at approximately $18,827,338.52. This trade represents a 0.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the business's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares in the company, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 325,922 shares of company stock valued at $51,603,664 in the last quarter. Corporate insiders own 7.60% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.